Androgenic alopecia |
Classification and external resources |
Male androgenic alopecia |
ICD-10 |
L64 |
DiseasesDB |
7773 |
MedlinePlus |
001177 |
eMedicine |
derm/21 |
MeSH |
D000505 |
Androgenic alopecia (also known as androgenetic alopecia, alopecia androgenetica, male pattern baldness) is loss of hair that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. It is the most common cause of hair loss and will affect up to 70% of men and 40% of women at some point in their lifetime. Men typically present with hairline recession at the temples and vertex balding while women normally diffusely thin over the top of their scalps.[1][2][3] Both genetic and environmental factors play a role, and many etiologies remain unknown.
Classic androgenic hair loss in males begins above the temples and vertex, or calvaria, of the scalp. As it progresses, a rim of hair at the sides and rear of the head remains. This has been referred to as a 'Hippocratic wreath', and rarely progresses to complete baldness.[4] The Hamilton-Norwood scale has been developed to grade androgenic alopecia in males.
Female androgenic alopecia has been colloquially referred to as 'female pattern baldness', although its characteristics can occur in males as well. It more often causes diffuse thinning without hairline recession, and like its male counterpart rarely leads to total hair loss.[5] The Ludwig scale grades severity of androgenic alopecia in females.
Human hair |
List of hairstyles
List of facial hairstyles |
By type |
Lanugo · Androgenic
Terminal · Vellus |
Facial hair |
Beard · Chin curtain · Chinstrap · Goatee · Handlebar moustache · Moustache · Neckbeard · Shenandoah · Sideburns · Soul patch · Stubble · Toothbrush moustache · Van Dyke |
Other areas |
Head · Nose · Ear · Underarm · Chest
Abdominal · Pubic · Leg |
Hair loss |
Baldness · Glabrousness
Hair removal
(waxing · threading · laser
IPL · chemical · electric · Plucking)
Shaving
(head · leg)
Razor |
Related topics |
Hairstyle · Hairdresser · Barber
Hair length · Hair color · Hair coloring
Hair fetishism · Pubic hair fetishism |
|
Animal models of androgenic alopecia occur naturally and have been developed in transgenic mice,[6] chimpanzees (Pan troglodytes), bald uakaris (Cacajao rubicundus) and stump-tailed macaques (Macaca speciosa and Macaca arctoides), of which the macaques demonstrate the greatest incidence and most prominent hair loss.[7][8]
Contents
- 1 Hormonal etiology
- 2 Genetics
- 3 Age effect
- 4 Androgenic impact of exercise
- 4.1 Aerobic
- 4.2 Anaerobic
- 4.3 Combined training
- 5 Female androgenic alopecia
- 6 Male homologue to PCOS
- 7 Evolutionary biology
- 8 Psychological effects
- 9 Diagnosis
- 10 Treatment
- 10.1 Conventional medicine
- 10.2 Alternative and future therapies
- 11 See also
- 12 References
- 13 External links
|
Hormonal etiology
Androgens can interact with the Wnt signalling pathway to cause to hair loss.
Researchers assert the initial programming of pilosebaceous units begins in utero.[9] The physiology is primarily androgenic, with dihydrotestosterone (DHT) the major contributor at the dermal papillae. Below normal values of SHBG, FSH, testosterone and epitestosterone are present in men with premature androgenic alopecia compared to normal controls.[10] Although follicles were previously thought permanently gone in areas of complete hair loss, they are more likely dormant, as recent studies have shown the scalp contains the stem cell progenitors from which the follicles arose.[11]
Transgenic studies have shown that growth and dormancy of hair follicles are related to the activity of IGF at the dermal papillae, which is affected by DHT.[12] Androgens are important in male sexual development around birth and at puberty. They regulate sebaceous glands, apocrine hair growth and libido. With increasing age,[13] androgens stimulate hair growth on the face, but suppress it at the temples and scalp vertex, a condition that has been referred to as the 'androgen paradox'.[14]
These observations have led to study at the level of the mesenchymal dermal papillae.[15][16] Type 1 and 2 5α reductase enzymes are present at pilosebaceous units in papillae of individual hair follicles.[17] They catalyze formation of the androgens testosterone and DHT, which in turn regulate hair growth.[14] Androgens have different effects at different follicles: they stimulate IGF-1 at facial hair, leading to growth, but stimulate TGF β1, TGF β2, dickkopf1 and IL-6 at the scalp, leading to catagenic miniaturization.[14] Hair follicles in anaphase express four different caspases. Tumor necrosis factor was found to inhibit elongation of hair follicles in vitro with abnormal morphology and cell death in the bulb matrix.[18]
Studies look at serum levels of IGF-1 show it to be increased with vertex balding.[19][20] Earlier work looking at in vitro administration of IGF had no effect on hair follicles when insulin was present, but when absent, caused follicle growth. The effects on hair of IGF-I were found greater than IGF-II.[21] Later work also showed IGF-1 signalling controls the hair growth cycle and differentiation of hair shafts,[22] possibly having an anti-apoptotic effect during the catagen phase.[23] In situ hybridization in adult human skin have shown morphogenic and mitogenic actions of IGF-1.[24] Mutations of the gene encoding IGF-1 result in shortened and morphologically bizarre hair growth and alopecia.[25] IGF-1 is modulated by IGF binding protein, which is produced in the dermal papilla.[26]
DHT inhibits IGF-1 at the dermal papillae.[27] Extracellular histones inhibit hair shaft elongation and promote regression of hair follicles by decreasing IGF and alkaline phosphatase in transgenic mice.[28] Silencing P-cadherin, a hair follicle protein at adherens junctions, decreases IGF-1, and increases TGF beta 2, although neutralizing TGF decreased catagenesis caused by loss of cadherin, suggesting additional molecular targets for therapy. P-cadherin mutants have short, sparse hair.[29]
At the occipital scalp, androgens enhance inducible nitric oxide synthase (iNOS), which catalyzes production of nitric oxide from L-arginine.[14] The induction of nitric oxide synthase usually occurs in an oxidative environment, where high levels of nitric oxide produced interact with superoxide, leading to peroxynitrite formation and cell toxicity. iNOS has been suggested to play a role in host immunity by participating in anti-microbial and anti-tumor activities as part of the oxidative burst[30] of macrophages.[31] The gene coding for nitric oxide synthase is on human chromosome 17.[32]
Hair follicle and mesenchymal dermal papilla, labelled at top.
There is also crosstalk between androgens and the Wnt-Beta-catenin signaling pathway that leads to hair loss. At the level of the somatic stem cell, androgens promote differentiation of facial hair dermal papillae, but inhibit it at the scalp.[14] Other research suggests the enzyme prostaglandin D2 synthase and its product prostaglandin D2 (PGD2) in hair follicles as contributive.[33]
Men with androgenic alopecia typically have higher 5-alpha-reductase, lower total testosterone, higher unbound/free testosterone and higher free androgens, including DHT.[10][34] 5-alpha-reductase converts free testosterone into DHT, and is highest in the scalp and prostate. DHT is most commonly formed at the tissue level by 5α-reduction of testosterone.[35] The genetic corollary that codes for this enzyme has been discovered.[36]
Prolactin has also been suggested to have different effects on the hair follicle across gender.[37] It seasonally modulates[38] and can delay[39] hair growth in animal models. In vitro models show it inhibits hair follicle growth.[40] In vivo it can inhibit facial hair growth in humans.[41] Researchers have suggested it works through paracrine action.[42]
Genetics
Individual pilosebaceous unit.
Since androgens and androgen receptors (AR) are the cause of androgenic alopecia, their genetic corollaries are a subject of much research. Some involved genes are X-linked, with men whose fathers show hair loss 2.5 times more likely to experience it themselves regardless of maternal report.[43] The maternal line is crucial as well, however, as it contains the androgen receptor gene, which provides the necessary diathesis for androgenic alopecia.[44]
The specific variant of the AR for baldness is on a recessive allele, so a woman would need two X chromosomes with the defect to show male pattern hair loss.[45] The EDA2R gene on the X chromosome at Xq11-q12, close to the area which codes for the androgen receptor gene, has been suggested by some researchers as specific to androgenic alopecia.[46] An allele on chromosome 3 at 3q26 also contributes.[47]
Genetic causes of hair texture and non-androgenic hair loss have been discovered as well. One is P2RY5, mutations of which affect hair structure and woolly hair.[48] Variants at this site can lead to baldness.[49] Other research identified the gene SOX21, Y-linked, as related to certain non-androgenic alopecias.[50]
Age effect
Two men practicing Tahtib, one of them with androgenic alopecia, on an Ostraca from Ancient Egypt, Louvre
Androgens stimulate growth of facial hair, but can suppress scalp hair, a condition which has been called the 'androgen paradox'.[14] The American Academy of Dermatology reports that in adult men, the incidence of androgenic alopecia is roughly equivalent to chronological age, with half of men experiencing hair loss by age 50.[51]
A number of hormonal changes occur with aging:
- Decrease in testosterone
- Decrease in DHT and 5-alpha reductase
- Decrease 3AAG, a peripheral marker of DHT metabolism,
- Increase in SHBG.
- Decrease in androgen receptors in the scalp with age.[52]
This decrease in androgens, androgen receptors and the increase in SHBG are opposite the increase in androgenic alopecia with aging. This is not intuitive, as testosterone and its peripheral metabolite, DHT, accelerate hair loss, and SHBG is thought to be protective. The ratio of T/SHBG, DHT/SHBG decreases by as much as 80% by age 80, in numeric parallel to hair loss, and approximates the pharmacology of anti-androgens such as finasteride.[51]
Free testosterone decreases in men by age 80 to levels double that of a woman at age 20. 30% of normal male testosterone level, the approximate level in females, is not enough to induce alopecia; 60%, closer to the amount found in elderly men, is sufficient.[53] It has been theorized that the testicular secretion of testosterone "sets the stage" for androgenic alopecia as a multifactorial diathesis stress model, related to hormonal predisposition, environment and age. Supplementing eunuchs with testosterone during their 2nd decade, for example, causes slow progression of androgenic alopecia over many years, while testosterone late in life causes rapid hair loss within a month.[54]
An example of premature age effect is Werner's syndrome, a condition of accelerated aging from low fidelity copying of mRNA. Affected children display premature androgenic alopecia.[55]
Androgenic impact of exercise
The impact of aerobic exercise on hair loss is different in acute and chronic settings.
Exercise can impact androgenic hair loss by affecting androgen and estrogen levels. The Rancho Bernardo Study, a large cross sectional examination of a community in southern California based on self report, found that among both genders there was no significant difference in premature graying or balding status related to alcohol, smoking, exercise, appropriate use of calcium supplements, diuretics, or thyroid medication. In women with androgenic alopecia, there was an increased association with corticosteroid and estrogen use. Self reports typically have less strength in the context of evidence based medicine and hormonal indices were not measured in this study.[56]
Quantification of androgen indices in response to exercise can be understood in four categories: short versus long term, and anaerobic versus aerobic. These are indirect assays of exercise impact on hair loss, although the ability of exogenous androgen to worsen or precipitate miniaturization in the genetically predisposed is well documented.[57] Investigations have been either self-report, or cross-sectional and cohort studies with exercise and serum hormonal indices, but no phase III clinical trials. In some studies, conflicting results are thought related to differences in exercise mode, volume, or physical condition of subjects.[58]
In cross-sectional analyses, aerobic exercisers have lower basal total and free testosterone compared to the sedentary.[59][60][61][62] Anaerobic exercisers also have lower testosterone compared to the sedentary[59] with slight increase in basal testosterone in resistance training over time.[63] There is some correlation between testosterone and physical activity in the middle aged and elderly.[64] Acutely, testosterone briefly increases when comparing aerobic, anaerobic and mixed forms of exercise.[65] A study assessed men who were resistance trained, endurance trained, or sedentary in which they either rested, ran or did a resistance session. Androgens increased in response to exercise, particularly resistance, while cortisol only increased with resistance. DHEA increased with resistance exercise and remained elevated during recovery in resistance-trained subjects. After initial post-exercise increase, there was decline in free and total testosterone during resistance recovery, particularly in resistance-trained subjects. Endurance-trained subjects showed less change in hormone levels in response to exercise than resistance-trained subjects.[66] Another study have found relative short term effects of aerobic, anaerobic and combined anaerobic-aerobic exercise protocols on hormone levels to not be different. It showed increases in testosterone and cortisol immediately after exercise that returned to baseline in 2 hours.[67]
Aerobic
In trained long term aerobic exercisers, basal levels are unchanged,[68] or decreased.[67][69] Acutely, endurance based aerobic efforts cause testosterone to rise.[70]
A year long, moderate-intensity aerobic exercise program increased DHT and SHBG in sedentary men age 40-75, but had no effect on other androgens. Both DHT and SHBG increased 14% in exercisers at 3 months, and at 12 months they remained 9% above baseline. SHBG is protective against DHT as it binds free androgen.[71] In acute assessment of hormone levels in soccer players before, during and after a game, DHT and testosterone increased during the match, but returned to baseline after 45 minutes rest.[72] Aerobic exercise in Japanese rats done on a rodent treadmill doubled local concentrations of DHT in calf muscles as assessed by protein assay.[73] After intense aerobic effort, high endurance athletes were also found to have lower free testosterone the next day.[74] In prolonged endurance exercise, such as a marathon, levels ultimately decrease.[75] Similarly, DHT drops, while adrenal androgen and cortisol will increase with the stress response.[76]
Anaerobic
Effects of anaerobic exercise also vary with length of time.
It is unknown if anaerobic training changes individual hormone profiles, or if conditioned athletes in studies self-selected because of physiologic predisposition to physical conditioning.[77] There is variation of response to anaerobic stress depending on exercise intensity, age, gender, length of time studied, and time at which serum indices were drawn. Most studies report that testosterone increases or is unchanged acutely, though some even report it to decrease. Anaerobic exercisers have testosterone levels below sedentary controls in cross sectional analysis. Over months to years, levels vary with intensity of training cycle in specific protocols, although follow up at two years has found baseline levels slightly increased.
The ratio of testosterone to cortisol can both increase[78] and decrease[79] during resistance training, depending on intensity of exercise. A study comparing young and old subjects showed acute increases in GH and testosterone for both, although the latter increased less in older men.[80] Testosterone rises in late hours of sleep after anaerobic exercise.[81] Androgen receptor expression increases with acute exercise in correlation to free testosterone.[82] When comparing men and women in the 30, 50 and 70 year age groups, young and middle aged men showed increased testosterone after exercise, with the latter also having increased cortisol. Elderly men showed no change.[83] Other studies have also shown with age there is a downtrend of testosterone[84] and attenuated growth hormone response.[85] Young men have shown no acute change in testosterone with resistance training, with increase in cortisol and growth hormone depending on intensity.[86] One study in young men showed testosterone acutely stable, with increase in GH and IGF-1.[87] Similarly, a study showed testosterone did not increase in young men, women, and pubescent boys unaccustomed to weight training when corrected for plasma volume.[88] Extreme intensity of strength training may trigger the stress response, resulting in lower testosterone levels,[89] an effect accentuated by energy deprivation.[90] A separate study comparing different ages, however, found no difference in acute testosterone and cortisol levels between groups, but attenuated growth hormone response in the elderly.[85] Acutely, other studies have shown testosterone to increase.[91] In a small group of anaerobically trained athletes, stressful training acutely even decreased serum testosterone and its ratio to cortisol and SHBG, with an increase in LH. With subsequent decompensation, testosterone was stable, but cortisol and SHBG decreased.[92] Another case control showed with intense training followed by rest, testosterone dropped and LH increased initially.[93]
Interval and quality of exercise also affect hormonal response. Sessions of moderate to high intensity with multiple sets and short time intervals, during which energy is derived from glycolytic lactate metabolism, appear to be the greatest stimulus for steroid hormone response. Hormonal response in young men varies with the number of sets in the exercise session. However, when the number increased from 4 to 6, anabolic levels stabilized and cortisol continued to rise, suggesting that alterations in anaerobic volume could alter anabolic and catabolic hormonal balance.[94] When sets are performed at maximum repetitions, interval has no influence at a certain intensity range, with no acute hormone response difference between protocols at 10 maximum reps with 2- and 5-minute intervals.[95] There is a higher total testosterone response in hypertrophy protocols compared to those for strength and power, despite equalization of total work load (defined as load x sets x repetitions).[96] There is a 27% greater testosterone response using protocols with simultaneous use of all four limbs. Androgenic response was also noted in protocols using upper and lower limbs separately to a lesser degree.[97]
A number of studies have looked at effects of anaerobic exercise over months to years, showing it to be constant or slightly increased. A small case-control of anaerobic training in young untrained males over six weeks found decline in free testosterone of 17 percent.[98] With men in their 60s, resistive training over 16 weeks did not affect baseline anabolic hormone levels, although GH increased acutely with exercise.[99] A study over 21 weeks in male strength athletes showed basal hormone levels to be constant, despite strength increase.[100] A follow up study looked at a larger group of weight trainers over 24 weeks, with 12 week decompensation. Training caused no change in total testosterone, but there were decreases in free testosterone, progesterone, androstendione, DHEA, cortisol, transcortin, and in the cortisol:CBG ratio, suggesting androgen turnover increased with training intensity, without change in total testosterone.[101] A study looking at young men and resistance training over 48 weeks found increases in baseline serum testosterone from 20 ± 5 to 25 ± 5 nmol/l, and an increase in testosterone:SHBG ratio, LH and FSH.[102]
Combined training
One study showed GH increase with anaerobic effort to be blunted in those who performed aerobic training for 60 minutes prior to strength training. Testosterone levels remained high only at the end of the training session with aerobic training followed by strength training, a phenomenon not seen with weight training done before aerobics.[103] In an 11 week soccer training program focusing on combined vertical jumps, short sprints, and submaximal endurance running, total testosterone increased, but SHBG rose in parallel, maintaining a constant free androgen index.[104]
Female androgenic alopecia
A recent cross sectional study on female monozygotic twins provided insight into female alopecia.
Female androgenic alopecia, clinically known as 'female pattern hair loss,' (FPHL) more often causes diffuse thinning without hairline recession. Approximately 30% of caucasian adult females experience hair loss.[105] Like its male counterpart, the condition rarely leads to total hair loss, although it is possible.[106] Treatment options to arrest progression and stimulate regrowth include finasteride, the androgen-independent growth promoter minoxidil, or androgen receptor antagonists spironolactone and cyproterone acetate. These work best initiated early, and hair transplantation can be considered in more advanced cases.[107]
A recently published study comparing monozygotic female twins found a number of factors associated with hair loss in women with varying degrees of statistical certainty, and stratified by pattern. Factors associated with increased temporal hair loss that were statistically significant (p < 0.05) were as follows:
- more children (p = 0.005)
- longer sleep duration (p = 0.006)
- diabetes mellitus (p = 0.008)
- lack of exercise (p = 0.012)
- hypertension (p = 0.027)
- divorce or separation (p = 0.034)
- multiple marriages (p = 0.040)
Frontal hair loss, like temporal, included hypertension (p = 0.001) and longer sleep duration (p = 0.011) as risk factors, but also included PCOS (p = 0.002), lack of hat use (p = 0.017), smoking (p = 0.021), high income (p = 0.023), diabetes mellitus (p = 0.023), stress (p = 0.034), and multiple marriages (p = 0.043).
Statistically significant causes of vertex hair loss were: lack of sun protection (p = 0.020), less caffeine (p = 0.040), and a history of skin disease (p = 0.048). Higher testosterone levels were associated with increased temporal and vertex hair loss patterns (p < 0.039). Stress, smoking, more children, and a history of hypertension or cancer were associated with increased hair thinning (p < 0.05). It is unknown to what degree factors contributing to female hair loss overlap with those in men.[108] Later studies have found that prolactin is unrelated to female androgenic pattern hair loss, despite earlier in vitro studies suggesting that it inhibited growth.[109] Female patients with mineralocorticoid resistance present with androgenic alopecia.[110] Older studies have found a slight relationship of prolactin with female androgenic hair loss.[111]
Male homologue to PCOS
A number of studies have found a link between androgenic alopecia and metabolic syndrome, suggesting the combination as a male homologue to PCOS.
Multiple cross sectional studies have found association between early androgenic alopecia, insulin resistance and metabolic syndrome,[112][113] with low HDL being the component of metabolic syndrome with highest association.[114] Linolenic and linoleic acids, two major dietary sources of HDL, are 5 alpha reductase inhibitors.[115] It has been suggested that premature androgenic alopecia and insulin resistance are a clinical constellation that represents the male homologue, or phenotype, of polycystic ovary syndrome.[116] Others have found a higher rate of hyperinsulinemia in family members of women with polycystic ovarian syndrome.[117]
In support of the association, finasteride improves glucose metabolism and decreases glycosylated hemoglobin HbA1c, a surrogate marker for diabetes mellitus.[118] The low SHBG seen with premature androgenic alopecia is also associated with, and likely contributory to, insulin resistance,[119] and for which it still is used as an assay for pediatric diabetes mellitus.[120]
Obesity leads to upregulation of insulin production and decrease in SHBG. Further reinforcing the relationship, SHBG is downregulated by insulin in vitro, although SHBG levels do not appear to affect insulin production.[121] In vivo, insulin stimulates both testosterone production and SHBG inhibition in normal and obese men.[122] The relationship between SHBG and insulin resistance has been known for some time; decades prior, ratios of SHBG and adiponectin were used before glucose to predict insulin resistance.[123] Patients with Laron syndrome, with resultant deficient IGF, demonstrate varying degrees of alopecia and structural defects in hair follicles when examined microscopically.[25]
Because of its association with metabolic syndrome and altered glucose metabolism, both men and women with early androgenic hair loss should be screened for impaired glucose tolerance and diabetes mellitus II.[124] A low fat and high fiber diet combined with regular aerobic exercise increases SHBG and insulin sensitivity.[125] Regarding androgenic impact of diet with exercise, a study found increased protein intake led to higher concentrations of free and total testosterone immediately post exercise.[126]
Measurement of subcutaneous and visceral adipose stores by MRI, demonstrated inverse association between visceral adipose and testosterone/DHT, while subcutaneous adipose correlated negatively with SHBG and positively with estrogen. Subcutaneous fat did not correlate with androgens once the SHBG relationship was taken into account.[127] SHBG association with fasting blood glucose is most dependent on intrahepatic fat, which can be measured by MRI in and out of phase imaging sequences. Serum indices of hepatic function and surrogate markers for diabetes, previously used, show less correlation with SHBG by comparison.[128]
Female patients with mineralocorticoid resistance present with androgenic alopecia.[129]
IGF levels have been found lower in those with metabolic syndrome.[130] Circulating serum levels of insulin Growth Factor-1 (IGF-1) are increased with vertex balding, although this study did not look at mRNA expression at the follicle itself.[20] Locally, IGF is mitogenic at the dermal papillae and promotes elongation of hair follicles. The major site of production of IGF is the liver, although local mRNA expression at hair follicles correlates with increase in hair growth. IGF release is stimulated by GH (growth hormone). Methods of increasing IGF include exercise, hypoglycemia, low fatty acids, deep sleep (stage IV REM), estrogens, and consumption of amino acids like arginine and leucine. Obesity and hyperglycemia inhibit its release. IGF also circulates in the blood bound to a large protein whose production is also dependent on GH. GH release is dependent on normal thyroid hormone. During the sixth decade of life, GH decreases in production. Because growth hormone is pulsatile and peaks during sleep, serum IGF is used as an index of overall growth hormone secretion. The surge of androgens at puberty drives an accompanying surge in growth hormone.[131]
Evolutionary biology
Certain studies have suggested androgenetic alopecia conveys survival advantage.
Some studies have suggested a survival advantage with androgenic alopecia.[132] Psychologists have noted when showing subjects people with difference appearances, decrease in cranial hair was associated with social maturity, appeasement, older age, and decreased attractiveness and aggressiveness.[133]
A study from South Korea showed most people rated balding men less attractive. Men and women viewed six male models with different levels of facial and cranial hair, and participants rated each combination on 32 adjectives related to social perception. Males with facial hair and those with bald or receding hair were rated as being older than those who were clean shaven or had a full head of hair. Beards and full heads of hair were seen as more aggressive, while baldness was associated with social maturity.[131]
More theories include that baldness signaled dominance, social status, or longevity.[134] Biologists have hypothesized the larger sunlight exposed area would allow more vitamin D to be synthesized, which might have been a "finely tuned mechanism to prevent prostate cancer," as the malignancy itself is also associated with higher levels of DHT.[135][136] Other hypotheses include genetic linkage to beneficial traits unrelated to hair loss and genetic drift.
Psychological effects
Androgenic alopecia is typically experienced as a "moderately stressful condition that diminishes body image satisfaction".[137] However, although most men regard baldness as an unwanted and distressing experience, they usually are able to cope and retain integrity of personality.[138]
Diagnosis
The diagnosis of androgenic alopecia can be usually established based on clinical presentation in men. In women, the diagnosis usually requires more complex diagnostic evaluation. Further evaluation of the differential requires exclusion of other causes of hair loss, and assessing for the typical progressive hair loss pattern of androgenic alopecia.[139] Trichoscopy can be used for further evaluation.[140] Biopsy may be needed to exclude other causes of hair loss,[141] and histology would demonstrate perifollicular fibrosis.[142][143]
Treatment
Main article: Management of androgenic alopecia
Conventional medicine
Early stages of hair loss can be slowed or reversed with medication, with FDA approved drugs being minoxidil and finasteride.[144] Topical formulations of finasteride have similar efficacy to systemic, though prostate weight and serum PSA levels were not measured to exclude systemic absorption of topical application as the cause of hair growth.[145] Other systemic options include the longer acting dutasteride and spironolactone, the latter of which has a high rate of feminizing side effects.[citation needed]
More advanced cases may be resistant or unresponsive to medical therapy, and require hair transplantation. Naturally-occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in close proximity and in large numbers. The grafts are obtained from either Follicular Unit Transplantation (FUT) or Follicular Unit Extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts. The surgeon then implants the grafts into small incisions, called recipient sites.[146][147] Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut.[148][149]
Alternative and future therapies
The field of research to prevent and treat androgenic hair loss is vast, with systemic and topical therapies with varying degrees of efficacy. In the United States alone, it is a multi-billion dollar industry. Low-level laser therapy (LLLT) claims to stimulate hair growth through "photo-biostimulation" of hair follicles, but has limited evidence of benefit or safety.[150] L-Carnitine induces hair growth in vitro.[151] TRX2, a hair loss supplement, includes it as the main ingredient. It is technically a dietary supplement, and not approved by the Food and Drug Administration.[152] Consumption of grateloupia elliptica, a red seaweed in Jeju Island, South Korea, has the potential to treat androgenic alopecia and alopecia areata.[153][154] Topical IGF in a liposomal vehicle thickens and elongates hair in transgenic mice with androgenic alopecia.[155] The enzyme prostaglandin D2 (PGD2) was present in the scalp of balding men at higher levels than those with hair, and prevented hair follicle maturation, with the possibility of treatment based on this research by 2014.[156][157][158]
See also
- Baldness
- Dihydrotestosterone
- Hamilton-Norwood scale
- Ludwig scale
- Management of baldness
- Noncicatricial alopecia
References
- ^ McElwee, K. J.; Shapiro, J. S. (2012). "Promising therapies for treating and/or preventing androgenic alopecia". Skin therapy letter 17 (6): 1–4. PMID 22735503. edit
- ^ Proctor, P. H. (1999). "Hair-raising. The latest news on male-pattern baldness". Advance for nurse practitioners 7 (4): 39–42, 83. PMID 10382384. edit
- ^ Leavitt, M. (2008). "Understanding and Management of Female Pattern Alopecia". Facial Plastic Surgery 24 (4): 414–427. doi:10.1055/s-0028-1102905. PMID 19034818. edit
- ^ "Hippocratic wreath (Baldness)". Britannica Online. Dec 15, 2012. http://www.britannica.com/EBchecked/topic/266655/Hippocratic-wreath. Retrieved Dec 15, 2012.
- ^ "Female pattern baldness". MedlinePlus. Dec 15, 2012. http://www.nlm.nih.gov/medlineplus/ency/article/001173.htm. Retrieved Dec 15, 2012.
- ^ Crabtree, J. S.; Kilbourne, E. J.; Peano, B. J.; Chippari, S.; Kenney, T.; McNally, C.; Wang, W.; Harris, H. A. et al. (2010). "A Mouse Model of Androgenetic Alopecia". Endocrinology 151 (5): 2373–2380. doi:10.1210/en.2009-1474. PMID 20233794. edit
- ^ Sundberg, J. P.; King, L. E.; Bascom, C. (2001). "Animal models for male pattern (androgenetic) alopecia". European journal of dermatology : EJD 11 (4): 321–325. PMID 11399538. edit
- ^ Sundberg, J. P.; Beamer, W. G.; Uno, H.; Van Neste, D.; King, L. E. (1999). "Androgenetic Alopecia: In Vivo Models". Experimental and Molecular Pathology 67 (2): 118–130. doi:10.1006/exmp.1999.2276. PMID 10527763. edit
- ^ Alonso, L. C.; Rosenfield, R. L. (2003). "Molecular genetic and endocrine mechanisms of hair growth". Hormone research 60 (1): 1–13. PMID 12792148. edit
- ^ a b Stárka, L.; Cermáková, I.; Dusková, M.; Hill, M.; Dolezal, M.; Polácek, V. (2004). "Hormonal Profile of Men with Premature Balding". Experimental and Clinical Endocrinology & Diabetes 112 (1): 24–28. doi:10.1055/s-2004-815723. PMID 14758568. edit
- ^ Garza, L. A.; Yang, C. C.; Zhao, T.; Blatt, H. B.; Lee, M.; He, H.; Stanton, D. C.; Carrasco, L. et al. (2011). "Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells". Journal of Clinical Investigation 121 (2): 613–622. doi:10.1172/JCI44478. PMC 3026732. PMID 21206086. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3026732/. edit
- ^ Weger, N.; Schlake, T. (2005). "IGF-I Signalling Controls the Hair Growth Cycle and the Differentiation of Hair Shafts". Journal of Investigative Dermatology 125 (5): 873–882. doi:10.1111/j.0022-202X.2005.23946.x. PMID 16297183. edit
- ^ "Help for Hair Loss: Men's Hair Loss – Causes". Webmd.com. Mar 1, 2010. http://www.webmd.com/skin-problems-and-treatments/hair-loss/hair-loss-causes.
- ^ a b c d e f Inui, S.; Itami, S. (2012). "Androgen actions on the human hair follicle: Perspectives". Experimental Dermatology: n/a. doi:10.1111/exd.12024. PMID 23016593. edit
- ^ Randall, V. A.; Hibberts, N. A.; Thornton, M. J.; Merrick, A. E.; Hamada, K.; Kato, S.; Jenner, T. J.; De Oliveira, I. et al. (2001). "Do androgens influence hair growth by altering the paracrine factors secreted by dermal papilla cells?". European journal of dermatology : EJD 11 (4): 315–320. PMID 11399537. edit
- ^ Soni, V. K. (2009). "Androgenic alopecia: A counterproductive outcome of the anabolic effect of androgens". Medical Hypotheses 73 (3): 420–426. doi:10.1016/j.mehy.2009.03.032. PMID 19477078. edit
- ^ Bernard, B. A. (1994). "Molecular approach of hair biology". Comptes rendus des seances de la Societe de biologie et de ses filiales 188 (3): 223–233. PMID 7834505. edit
- ^ Soma, T.; Ogo, M.; Suzuki, J.; Takahashi, T.; Hibino, T. (1998). "Analysis of Apoptotic Cell Death in Human Hair Follicles in Vivo and in Vitro". Journal of Investigative Dermatology 111 (6): 948–954. doi:10.1046/j.1523-1747.1998.00408.x. PMID 9856801. edit
- ^ Platz, E. A.; Pollak, M. N.; Willett, W. C.; Giovannucci, E. (2000). "Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3". Journal of the American Academy of Dermatology 42 (6): 1003–1007. PMID 10827403. edit
- ^ a b Signorello, L. B.; Wuu, J.; Hsieh, C.; Tzonou, A.; Trichopoulos, D.; Mantzoros, C. S. (1999). "Hormones and hair patterning in men: A role for insulin-like growth factor 1?". Journal of the American Academy of Dermatology 40 (2 Pt 1): 200–203. PMID 10025745. edit
- ^ Philpott, M. P.; Sanders, D. A.; Kealey, T. (1994). "Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro". The Journal of investigative dermatology 102 (6): 857–861. PMID 8006448. edit
- ^ Weger, N.; Schlake, T. (2005). "IGF-I Signalling Controls the Hair Growth Cycle and the Differentiation of Hair Shafts". Journal of Investigative Dermatology 125 (5): 873–882. doi:10.1111/j.0022-202X.2005.23946.x. PMID 16297183. edit
- ^ Su, H. Y.; Hickford, J. G.; Bickerstaffe, R.; Palmer, B. R. (1999). "Insulin-like growth factor 1 and hair growth". Dermatology online journal 5 (2): 1. PMID 10673454. edit
- ^ Rudman, S. M.; Philpott, M. P.; Thomas, G. A.; Kealey, T. (1997). "The Role of IGF-I in Human Skin and its Appendages: Morphogen as Well as Mitogen?". Journal of Investigative Dermatology 109 (6): 770–777. doi:10.1111/1523-1747.ep12340934. PMID 9406819. edit
- ^ a b Lurie, R.; Ben-Amitai, D.; Laron, Z. (2004). "Laron Syndrome (Primary Growth Hormone Insensitivity): A Unique Model to Explore the Effect of Insulin-Like Growth Factor 1 Deficiency on Human Hair". Dermatology 208 (4): 314–318. doi:10.1159/000077839. PMID 15178913. edit
- ^ Batch, J. A.; Mercuri, F. A.; Werther, G. A. (1996). "Identification and localization of insulin-like growth factor-binding protein (IGFBP) messenger RNAs in human hair follicle dermal papilla". The Journal of investigative dermatology 106 (3): 471–475. PMID 8648179. edit
- ^ Zhao, J.; Harada, N.; Okajima, K. (2011). "Dihydrotestosterone inhibits hair growth in mice by inhibiting insulin-like growth factor-I production in dermal papillae". Growth Hormone & IGF Research 21 (5): 260–267. doi:10.1016/j.ghir.2011.07.003. PMID 21839661. edit
- ^ Shin, S. H.; Joo, H. W.; Kim, M. K.; Kim, J. C.; Sung, Y. K. (2012). "Extracellular histones inhibit hair shaft elongation in cultured human hair follicles and promote regression of hair follicles in mice". Experimental Dermatology 21 (12): 956–958. doi:10.1111/exd.12033. PMID 23171459. edit
- ^ Samuelov, L.; Sprecher, E.; Tsuruta, D.; Bíró, T. S.; Kloepper, J. E.; Paus, R. (2012). "P-Cadherin Regulates Human Hair Growth and Cycling via Canonical Wnt Signaling and Transforming Growth Factor-β2". Journal of Investigative Dermatology 132 (10): 2332–2341. doi:10.1038/jid.2012.171. PMID 22696062. edit
- ^ Marletta, M. A.; Yoon, P. S.; Iyengar, R.; Leaf, C. D.; Wishnok, J. S. (1988). "Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate". Biochemistry 27 (24): 8706–8711. PMID 3242600. edit
- ^ Mungrue, I. N.; Husain, M.; Stewart, D. J. (2002). "The role of NOS in heart failure: Lessons from murine genetic models". Heart failure reviews 7 (4): 407–422. PMID 12379825. edit
- ^ Knowles, R. G.; Moncada, S. (1994). "Nitric oxide synthases in mammals". The Biochemical journal 298 ( Pt 2) (Pt 2): 249–258. PMC 1137932. PMID 7510950. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1137932/. edit
- ^ Garza, L. A.; Liu, Y.; Yang, Z.; Alagesan, B.; Lawson, J. A.; Norberg, S. M.; Loy, D. E.; Zhao, T. et al. (2012). "Prostaglandin D2 Inhibits Hair Growth and is Elevated in Bald Scalp of Men with Androgenetic Alopecia". Science Translational Medicine 4 (126): 126ra34. doi:10.1126/scitranslmed.3003122. PMC 3319975. PMID 22440736. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3319975/. edit
- ^ Demark-Wahnefried, W.; Lesko, S. M.; Conaway, M. R.; Robertson, C. N.; Clark, R. V.; Lobaugh, B.; Mathias, B. J.; Strigo, T. S. et al. (1997). "Serum androgens: Associations with prostate cancer risk and hair patterning". Journal of andrology 18 (5): 495–500. PMID 9349747. edit
- ^ Kaufman, J. M.; Vermeulen, A. (2005). "The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications". Endocrine Reviews 26 (6): 833–876. doi:10.1210/er.2004-0013. PMID 15901667. edit
- ^ Ellis, J. A.; Panagiotopoulos, S.; Akdeniz, A.; Jerums, G.; Harrap, S. B. (2005). "Androgenic correlates of genetic variation in the gene encoding 5α-reductase type 1". Journal of Human Genetics 50 (10): 534–537. doi:10.1007/s10038-005-0289-x. PMID 16155734. edit
- ^ Langan, E. A.; Ramot, Y.; Goffin, V.; Griffiths, C. E. M.; Foitzik, K.; Paus, R. (2009). "Mind the (Gender) Gap: Does Prolactin Exert Gender and/or Site-Specific Effects on the Human Hair Follicle?". Journal of Investigative Dermatology 130 (3): 886–891. doi:10.1038/jid.2009.340. PMID 19890346. edit
- ^ Foitzik, K.; Langan, E. A.; Paus, R. (2008). "Prolactin and the Skin: A Dermatological Perspective on an Ancient Pleiotropic Peptide Hormone". Journal of Investigative Dermatology 129 (5): 1071–1087. doi:10.1038/jid.2008.348. PMID 19110541. edit
- ^ Craven, A. J.; Nixon, A. J.; Ashby, M. G.; Ormandy, C. J.; Blazek, K.; Wilkins, R. J.; Pearson, A. J. (2006). "Prolactin delays hair regrowth in mice". Journal of Endocrinology 191 (2): 415–425. doi:10.1677/joe.1.06685. PMID 17088411. edit
- ^ Foitzik, K.; Krause, K.; Conrad, F.; Nakamura, M.; Funk, W.; Paus, R. (2006). "Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine Promoter of Apoptosis-Driven Hair Follicle Regression". The American Journal of Pathology 168 (3): 748–756. doi:10.2353/ajpath.2006.050468. PMC 1606541. PMID 16507890. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1606541/. edit
- ^ Steinhoff, M.; Rochlitz, H.; Nußbaum, G.; Georgieva, J.; Zouboulis, C. C. (2007). "Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma". Journal of the European Academy of Dermatology and Venereology 21 (1): 124–126. doi:10.1111/j.1468-3083.2006.01811.x. PMID 17207191. edit
- ^ Foitzik, K.; Krause, K.; Nixon, A. J.; Ford, C. A.; Ohnemus, U.; Pearson, A. J.; Paus, R. (2003). "Prolactin and Its Receptor Are Expressed in Murine Hair Follicle Epithelium, Show Hair Cycle-Dependent Expression, and Induce Catagen". The American Journal of Pathology 162 (5): 1611–1621. doi:10.1016/S0002-9440(10)64295-2. PMC 1851183. PMID 12707045. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1851183/. edit
- ^ Chumlea, W. C.; Rhodes, T.; Girman, C. J.; Johnson-Levonas, A.; Lilly, F. R. W.; Wu, R.; Guo, S. S. (2004). "Family History and Risk of Hair Loss". Dermatology 209 (1): 33–39. doi:10.1159/000078584. PMID 15237265. edit
- ^ Hillmer, A. M.; Hanneken, S.; Ritzmann, S.; Becker, T.; Freudenberg, J.; Brockschmidt, F. F.; Flaquer, A.; Freudenberg-Hua, Y. et al. (2005). "Genetic Variation in the Human Androgen Receptor Gene is the Major Determinant of Common Early-Onset Androgenetic Alopecia". The American Journal of Human Genetics 77 (1): 140–148. doi:10.1086/431425. PMC 1226186. PMID 15902657. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1226186/. edit
- ^ Levy-Nissenbaum, E.; Bar-Natan, M.; Frydman, M.; Pras, E. (2005). "Confirmation of the association between male pattern baldness and the androgen receptor gene". European journal of dermatology : EJD 15 (5): 339–340. PMID 16172040. edit
- ^ Prodi, D. A.; Pirastu, N.; Maninchedda, G.; Sassu, A.; Picciau, A.; Palmas, M. A.; Mossa, A.; Persico, I. et al. (2008). "EDA2R is Associated with Androgenetic Alopecia". Journal of Investigative Dermatology 128 (9): 2268–2270. doi:10.1038/jid.2008.60. PMID 18385763. edit
- ^ Hillmer, A. M.; Flaquer, A.; Hanneken, S.; Eigelshoven, S.; Kortüm, A. K.; Brockschmidt, F. F.; Golla, A.; Metzen, C. et al. (2008). "Genome-wide Scan and Fine-Mapping Linkage Study of Androgenetic Alopecia Reveals a Locus on Chromosome 3q26". The American Journal of Human Genetics 82 (3): 737–743. doi:10.1016/j.ajhg.2007.11.014. PMC 2427264. PMID 18304493. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2427264/. edit
- ^ Shimomura, Y.; Wajid, M.; Ishii, Y.; Shapiro, L.; Petukhova, L.; Gordon, D.; Christiano, A. M. (2008). "Disruption of P2RY5, an orphan G protein–coupled receptor, underlies autosomal recessive woolly hair". Nature Genetics 40 (3): 335–339. doi:10.1038/ng.100. PMID 18297072. edit
- ^ Petukhova, L.; Sousa, E. C.; Martinez-Mir, A.; Vitebsky, A.; Dos Santos, L. G.; Shapiro, L.; Haynes, C.; Gordon, D. et al. (2008). "Genome-wide linkage analysis of an autosomal recessive hypotrichosis identifies a novel P2RY5 mutation". Genomics 92 (5): 273–278. doi:10.1016/j.ygeno.2008.06.009. PMC 3341170. PMID 18692127. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3341170/. edit
- ^ "Scientists identify gene that may explain hair loss". Reuters. 2009-05-25. http://uk.reuters.com/article/scienceNews/idUKTRE54O4D020090525.
- ^ a b "The Bald Truth About Hair Loss In Young Men". Stephanie Whyche, InteliHealth News Service. Aug 8, 2002. http://www.intelihealth.com/IH/ihtIH/WSIHW000/9023/24253/352721.html?d=dmtContent. Retrieved Dec 16, 2012.
- ^ European Hair Research Society - Abstract (conference). http://www.ehrs.org/conferenceabstracts/2001tokyo/researchabstracts/140-price.htm.
- ^ Hamilton, James B. (Nov 1942). "Male Hormone Stimulation Is Prerequisite and an Incident in Common Baldness". American Journal of Anatomy: 451–458.
- ^ Hamilton, J. B. (1951). "Patterned loss of hair in man; types and incidence". Annals of the New York Academy of Sciences 53 (3): 708–728. PMID 14819896. edit
- ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
- ^ Morton, D. J.; Kritz-Silverstein, D.; Riley, D. J.; Barrett-Connor, E. L.; Wingard, D. L. (2007). "Premature Graying, Balding, and Low Bone Mineral Density in Older Women and Men: The Rancho Bernardo Study". Journal of Aging and Health 19 (2): 275–285. doi:10.1177/0898264307299274. PMC 2642646. PMID 17413136. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2642646/. edit
- ^ Giorgi, A.; Weatherby, R. P.; Murphy, P. W. (1999). "Muscular strength, body composition and health responses to the use of testosterone enanthate: A double blind study". Journal of science and medicine in sport / Sports Medicine Australia 2 (4): 341–355. PMID 10710012. edit
- ^ Tremblay, M. S.; Copeland, J. L.; Van Helder, W. (2004). "Effect of training status and exercise mode on endogenous steroid hormones in men". Journal of Applied Physiology 96 (2): 531–539. doi:10.1152/japplphysiol.00656.2003. PMID 14514704. edit
- ^ a b Arce, J. C.; De Souza, M. J.; Pescatello, L. S.; Luciano, A. A. (1993). "Subclinical alterations in hormone and semen profile in athletes". Fertility and sterility 59 (2): 398–404. PMID 8425638. edit
- ^ Hackney, A. C.; Sinning, W. E.; Bruot, B. C. (1988). "Reproductive hormonal profiles of endurance-trained and untrained males". Medicine and science in sports and exercise 20 (1): 60–65. PMID 3343919. edit
- ^ Wheeler, G. D.; Wall, S. R.; Belcastro, A. N.; Cumming, D. C. (1984). "Reduced serum testosterone and prolactin levels in male distance runners". JAMA : the journal of the American Medical Association 252 (4): 514–516. PMID 6429357. edit
- ^ Cooper, C. S.; Taaffe, D. R.; Guido, D.; Packer, E.; Holloway, L.; Marcus, R. (1998). "Relationship of chronic endurance exercise to the somatotropic and sex hormone status of older men". European journal of endocrinology / European Federation of Endocrine Societies 138 (5): 517–523. PMID 9625362. edit
- ^ Häkkinen, K.; Pakarinen, A.; Alen, M.; Kauhanen, H.; Komi, P. V. (1988). "Neuromuscular and hormonal adaptations in athletes to strength training in two years". Journal of applied physiology (Bethesda, Md. : 1985) 65 (6): 2406–2412. PMID 3215840. edit
- ^ Muller, M.; Den Tonkelaar, I.; Thijssen, J. H.; Grobbee, D. E.; Van Der Schouw, Y. T. (2003). "Endogenous sex hormones in men aged 40-80 years". European journal of endocrinology / European Federation of Endocrine Societies 149 (6): 583–589. PMID 14641001. edit
- ^ Kraemer, W. J.; Häkkinen, K.; Newton, R. U.; McCormick, M.; Nindl, B. C.; Volek, J. S.; Gotshalk, L. A.; Fleck, S. J. et al. (1998). "Acute hormonal responses to heavy resistance exercise in younger and older men". European journal of applied physiology and occupational physiology 77 (3): 206–211. PMID 9535580. edit
- ^ Tremblay, M. S.; Copeland, J. L.; Van Helder, W. (2004). "Effect of training status and exercise mode on endogenous steroid hormones in men". Journal of Applied Physiology 96 (2): 531–539. doi:10.1152/japplphysiol.00656.2003. PMID 14514704. edit
- ^ a b Hackney, A. C.; Premo, M. C.; McMurray, R. G. (1995). "Influence of aerobic versus anaerobic exercise on the relationship between reproductive hormones in men". Journal of Sports Sciences 13 (4): 305–311. doi:10.1080/02640419508732244. PMID 7474044. edit
- ^ Fellmann, N.; Coudert, J.; Jarrige, J. -F.; Bedu, M.; Denis, C.; Boucher, D.; Lacour, J. -R. (2008). "Effects of Endurance Training on the Androgenic Response to Exercise in Man". International Journal of Sports Medicine 06 (4): 215–219. doi:10.1055/s-2008-1025843. PMID 4044106. edit
- ^ Hackney, A. C.; Fahrner, C. L.; Gulledge, T. P. (1998). "Basal reproductive hormonal profiles are altered in endurance trained men". The Journal of sports medicine and physical fitness 38 (2): 138–141. PMID 9763799. edit
- ^ Jensen, J.; Oftebro, H.; Breigan, B.; Johnsson, A.; Ohlin, K.; Meen, H. D.; Strømme, S. B.; Dahl, H. A. (1991). "Comparison of changes in testosterone concentrations after strength and endurance exercise in well trained men". European journal of applied physiology and occupational physiology 63 (6): 467–471. PMID 1765061. edit
- ^ Hawkins, V. N.; Foster-Schubert, K.; Chubak, J.; Sorensen, B.; Ulrich, C. M.; Stancyzk, F. Z.; Plymate, S.; Stanford, J. et al. (2008). "Effect of Exercise on Serum Sex Hormones in Men". Medicine & Science in Sports & Exercise 40 (2): 223–233. doi:10.1249/mss.0b013e31815bbba9. PMC 3040039. PMID 18202581. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3040039/. edit
- ^ Lupo, C.; Baldi, L.; Bonifazi, M.; Lodi, L.; Martelli, G.; Viti, A.; Carli, G. (1985). "Androgen levels following a football match". European journal of applied physiology and occupational physiology 54 (5): 494–496. PMID 4085477. edit
- ^ Sato, K.; Iemitsu, M.; Aizawa, K.; Mesaki, N.; Ajisaka, R.; Fujita, S. (2012). "DHEA administration and exercise training improves insulin resistance in obese rats". Nutrition & Metabolism 9: 47. doi:10.1186/1743-7075-9-47. PMC 3433349. PMID 22647230. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3433349/. edit
- ^ Daly, W.; Seegers, C. A.; Rubin, D. A.; Dobridge, J. D.; Hackney, A. C. (2004). "Relationship between stress hormones and testosterone with prolonged endurance exercise". European Journal of Applied Physiology 93 (4): 375–380. doi:10.1007/s00421-004-1223-1. PMID 15618989. edit
- ^ Dressendorfer, R. H.; Wade, C. E. (1991). "Effects of a 15-d race on plasma steroid levels and leg muscle fitness in runners". Medicine and science in sports and exercise 23 (8): 954–958. PMID 1956271. edit
- ^ Morville, R.; Pesquies, P. C.; Guezennec, C. Y.; Serrurier, B. D.; Guignard, M. (1979). "Plasma variations in testicular and adrenal androgens during prolonged physical exercise in man". Annales d'endocrinologie 40 (5): 501–510. PMID 518032. edit
- ^ Bunt, J. C. (1986). "Hormonal alterations due to exercise". Sports medicine (Auckland, N.Z.) 3 (5): 331–345. PMID 3529282. edit
- ^ Alén, M.; Pakarinen, A.; Häkkinen, K.; Komi, P. V. (1988). "Responses of serum androgenic-anabolic and catabolic hormones to prolonged strength training". International journal of sports medicine 9 (3): 229–233. PMID 3410630. edit
- ^ Häkkinen, K.; Pakarinen, A.; Alén, M.; Kauhanen, H.; Komi, P. V. (1987). "Relationships between training volume, physical performance capacity, and serum hormone concentrations during prolonged training in elite weight lifters". International journal of sports medicine 8 Suppl 1: 61–65. PMID 3108174. edit
- ^ Häkkinen, K.; Pakarinen, A.; Newton, R. U.; Kraemer, W. J. (1998). "Acute hormone responses to heavy resistance lower and upper extremity exercise in young versus old men". European journal of applied physiology and occupational physiology 77 (4): 312–319. PMID 9562359. edit
- ^ McMurray, R. G.; Eubank, T. K.; Hackney, A. C. (1995). "Nocturnal hormonal responses to resistance exercise". European journal of applied physiology and occupational physiology 72 (1–2): 121–126. PMID 8789582. edit
- ^ Willoughby, D. S.; Taylor, L. (2004). "Effects of sequential bouts of resistance exercise on androgen receptor expression". Medicine and science in sports and exercise 36 (9): 1499–1506. PMID 15354030. edit
- ^ Häkkinen, K.; Pakarinen, A. (2007). "Acute Hormonal Responses to Heavy Resistance Exercise in Men and Women at Different Ages". International Journal of Sports Medicine 16 (8): 507–513. doi:10.1055/s-2007-973045. PMID 8776203. edit
- ^ Baker, J. R.; Bemben, M. G.; Anderson, M. A.; Bemben, D. A. (2006). "Effects of Age on Testosterone Responses to Resistance Exercise and Musculoskeletal Variables in Men". The Journal of Strength and Conditioning Research 20 (4): 874–881. doi:10.1519/R-18885.1. PMID 17194250. edit
- ^ a b Smilios, I.; Pilianidis, T.; Karamouzis, M.; Parlavantzas, A.; Tokmakidis, S. (2007). "Hormonal Responses after a Strength Endurance Resistance Exercise Protocol in Young and Elderly Males". International Journal of Sports Medicine 28 (5): 401–406. doi:10.1055/s-2006-924366. PMID 17024619. edit
- ^ Smilios, I.; Pilianidis, T.; Karamouzis, M.; Tokmakidis, S. P. (2003). "Hormonal Responses after Various Resistance Exercise Protocols". Medicine & Science in Sports & Exercise 35 (4): 644–654. doi:10.1249/01.MSS.0000058366.04460.5F. PMID 12673149. edit
- ^ Pullinen, T.; Mero, A.; Huttunen, P.; Pakarinen, A.; Komi, P. V. (2002). "Resistance exercise-induced hormonal responses in men, women, and pubescent boys". Medicine and science in sports and exercise 34 (5): 806–813. PMID 11984299. edit
- ^ Kraemer, R. R.; Kilgore, J. L.; Kraemer, G. R.; Castracane, V. D. (1992). "Growth hormone, IGF-I, and testosterone responses to resistive exercise". Medicine and science in sports and exercise 24 (12): 1346–1352. PMID 1470017. edit
- ^ Raastad, T.; Glomsheller, T.; BjøRo, T.; Hallén, J. (2001). "Changes in human skeletal muscle contractility and hormone status during 2 weeks of heavy strength training". European Journal of Applied Physiology 84 (1–2): 54–63. doi:10.1007/s004210000328. PMID 11394254. edit
- ^ Bergendahl, M.; Aloi, J. A.; Iranmanesh, A.; Mulligan, T. M.; Veldhuis, J. D. (1998). "Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men". The Journal of clinical endocrinology and metabolism 83 (6): 1967–1975. doi:10.1210/jc.83.6.1967. PMID 9626127. edit
- ^ Kraemer, W. J.; Marchitelli, L.; Gordon, S. E.; Harman, E.; Dziados, J. E.; Mello, R.; Frykman, P.; McCurry, D. et al. (1990). "Hormonal and growth factor responses to heavy resistance exercise protocols". Journal of applied physiology (Bethesda, Md. : 1985) 69 (4): 1442–1450. PMID 2262468. edit
- ^ Häkkinen, K.; Pakarinen, A.; Alén, M.; Kauhanen, H.; Komi, P. V. (1987). "Relationships between training volume, physical performance capacity, and serum hormone concentrations during prolonged training in elite weight lifters". International journal of sports medicine 8 Suppl 1: 61–65. PMID 3108174. edit
- ^ Busso, T.; Häkkinen, K.; Pakarinen, A.; Kauhanen, H.; Komi, P. V.; Lacour, J. R. (1992). "Hormonal adaptations and modelled responses in elite weightlifters during 6 weeks of training". European journal of applied physiology and occupational physiology 64 (4): 381–386. PMID 1592066. edit
- ^ Smilios, I.; Pilianidis, T.; Karamouzis, M.; Tokmakidis, S. P. (2003). "Hormonal Responses after Various Resistance Exercise Protocols". Medicine & Science in Sports & Exercise 35 (4): 644–654. doi:10.1249/01.MSS.0000058366.04460.5F. PMID 12673149. edit
- ^ Ahtiainen, J. P.; Pakarinen, A.; Alen, M.; Kraemer, W. J.; Häkkinen, K. (2005). "Short vs. Long Rest Period Between the Sets in Hypertrophic Resistance Training: Influence on Muscle Strength, Size, and Hormonal Adaptations in Trained Men". The Journal of Strength and Conditioning Research 19 (3): 572–582. doi:10.1519/15604.1. PMID 16095405. edit
- ^ McCaulley, G. O.; McBride, J. M.; Cormie, P.; Hudson, M. B.; Nuzzo, J. L.; Quindry, J. C.; Travis Triplett, N. (2008). "Acute hormonal and neuromuscular responses to hypertrophy, strength and power type resistance exercise". European Journal of Applied Physiology 105 (5): 695–704. doi:10.1007/s00421-008-0951-z. PMID 19066934. edit
- ^ Häkkinen, K.; Pakarinen, A.; Newton, R. U.; Kraemer, W. J. (1998). "Acute hormone responses to heavy resistance lower and upper extremity exercise in young versus old men". European journal of applied physiology and occupational physiology 77 (4): 312–319. PMID 9562359. edit
- ^ Ara, I.; Perez-Gomez, J.; Vicente-Rodriguez, G.; Chavarren, J.; Dorado, C.; Calbet, J. A. (2006). "Serum free testosterone, leptin and soluble leptin receptor changes in a 6-week strength-training programme". The British journal of nutrition 96 (6): 1053–1059. PMID 17181880. edit
- ^ Nicklas, B.; Ryan, A.; Treuth, M.; Harman, S.; Blackman, M.; Hurley, B.; Rogers, M. (2007). "Testosterone, Growth Hormone and IGF-I Responses to Acute and Chronic Resistive Exercise in Men Aged 55-70 Years". International Journal of Sports Medicine 16 (7): 445–450. doi:10.1055/s-2007-973035. PMID 8550252. edit
- ^ Ahtiainen, J. P.; Pakarinen, A.; Alen, M.; Kraemer, W. J.; h�Kkinen, K. (2003). "Muscle hypertrophy, hormonal adaptations and strength development during strength training in strength-trained and untrained men". European Journal of Applied Physiology 89 (6): 555–563. doi:10.1007/s00421-003-0833-3. PMID 12734759. edit
- ^ Alén, M.; Pakarinen, A.; Häkkinen, K.; Komi, P. V. (1988). "Responses of serum androgenic-anabolic and catabolic hormones to prolonged strength training". International journal of sports medicine 9 (3): 229–233. PMID 3410630. edit
- ^ Häkkinen, K.; Pakarinen, A.; Alen, M.; Kauhanen, H.; Komi, P. V. (1988). "Neuromuscular and hormonal adaptations in athletes to strength training in two years". Journal of applied physiology (Bethesda, Md. : 1985) 65 (6): 2406–2412. PMID 3215840. edit
- ^ Goto, K.; Higashiyama, M.; Ishii, N.; Takamatsu, K. (2005). "Prior endurance exercise attenuates growth hormone response to subsequent resistance exercise". European Journal of Applied Physiology 94 (3): 333–338. doi:10.1007/s00421-004-1296-x. PMID 15714290. edit
- ^ Gorostiaga, E. M.; Izquierdo, M.; Ruesta, M.; Iribarren, J.; Gonz�Lez-Badillo, J. J.; Ib��Ez, J. (2003). "Strength training effects on physical performance and serum hormones in young soccer players". European Journal of Applied Physiology 91 (5–6): 698–707. doi:10.1007/s00421-003-1032-y. PMID 14704801. edit
- ^ Sinclair, R.; Patel, M.; Dawson, T. L.; Yazdabadi, A.; Yip, L.; Perez, A.; Rufaut, N. W. (2011). "Hair loss in women: Medical and cosmetic approaches to increase scalp hair fullness". British Journal of Dermatology 165: 12–18. doi:10.1111/j.1365-2133.2011.10630.x. PMID 22171680. edit
- ^ Sinclair, R.; Patel, M.; Dawson, T. L.; Yazdabadi, A.; Yip, L.; Perez, A.; Rufaut, N. W. (2011). "Hair loss in women: Medical and cosmetic approaches to increase scalp hair fullness". British Journal of Dermatology 165: 12–18. doi:10.1111/j.1365-2133.2011.10630.x. PMID 22171680. edit
- ^ Sinclair, R.; Patel, M.; Dawson, T. L.; Yazdabadi, A.; Yip, L.; Perez, A.; Rufaut, N. W. (2011). "Hair loss in women: Medical and cosmetic approaches to increase scalp hair fullness". British Journal of Dermatology 165: 12–18. doi:10.1111/j.1365-2133.2011.10630.x. PMID 22171680. edit
- ^ Gatherwright, J.; Liu, M. T.; Gliniak, C.; Totonchi, A.; Guyuron, B. (2012). "The Contribution of Endogenous and Exogenous Factors to Female Alopecia". Plastic and Reconstructive Surgery 130 (6): 1219–1226. doi:10.1097/PRS.0b013e31826d104f. PMID 22878477. edit
- ^ Lutz, G. (2012). "Hair loss and hyperprolactinemia in women". Dermato-Endocrinology 4 (1): 65–71. doi:10.4161/derm.19472. PMC 3408995. PMID 22870355. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3408995/. edit
- ^ Van Rossum, E. F. C.; Lamberts, S. W. J. (2006). "Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach". Best Practice & Research Clinical Endocrinology & Metabolism 20 (4): 611–626. doi:10.1016/j.beem.2006.09.005. PMID 17161335. edit
- ^ Schmidt, J. B. (1994). "Hormonal basis of male and female androgenic alopecia: Clinical relevance". Skin pharmacology : the official journal of the Skin Pharmacology Society 7 (1–2): 61–66. PMID 8003325. edit
- ^ Acibucu, F.; Kayatas, M.; Candan, F. (2010). "The association of insulin resistance and metabolic syndrome in early androgenetic alopecia". Singapore medical journal 51 (12): 931–936. PMID 21221497. edit
- ^ González-González, J. G.; Mancillas-Adame, L. G.; Fernández-Reyes, M.; Gómez-Flores, M.; Lavalle-González, F. J.; Ocampo-Candiani, J.; Villarreal-Pérez, J. S. Z. A. (2009). "Androgenetic alopecia and insulin resistance in young men". Clinical Endocrinology 71 (4): 494–499. doi:10.1111/j.1365-2265.2008.03508.x. PMID 19094069. edit
- ^ Su, L. H.; Chen, T. H. H. (2010). "Association of androgenetic alopecia with metabolic syndrome in men: A community-based survey". British Journal of Dermatology 163 (2): 371–377. doi:10.1111/j.1365-2133.2010.09816.x. PMID 20426781. edit
- ^ Liang, T.; Liao, S. (1992). "Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids". The Biochemical journal 285 ( Pt 2) (Pt 2): 557–562. PMC 1132824. PMID 1637346. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1132824/. edit
- ^ Legro, R. S. (2000). "Is there a male phenotype in polycystic ovary syndrome families?". Journal of pediatric endocrinology & metabolism : JPEM 13 Suppl 5: 1307–1309. PMID 11117676. edit
- ^ Norman, R. J.; Masters, S.; Hague, W. (1996). "Hyperinsulinemia is common in family members of women with polycystic ovary syndrome". Fertility and sterility 66 (6): 942–947. PMID 8941059. edit
- ^ Duskova, M.; Hill, M.; Starka, L. (2010). "Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride". Endocrine regulations 44 (1): 3–8. PMID 20151762. edit
- ^ Pugeat, M.; Crave, J. C.; Elmidani, M.; Nicolas, M. H.; Garoscio-Cholet, M.; Lejeune, H.; Déchaud, H.; Tourniaire, J. (1991). "Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin". The Journal of steroid biochemistry and molecular biology 40 (4–6): 841–849. PMID 1958579. edit
- ^ Gascón, F.; Valle, M.; Martos, R.; Ruz, F. J.; Ríos, R.; Montilla, P.; Cañete, R. (2000). "Sex hormone-binding globulin as a marker for hyperinsulinemia and/or insulin resistance in obese children". European journal of endocrinology / European Federation of Endocrine Societies 143 (1): 85–89. PMID 10870035. edit
- ^ Strain, G.; Zumoff, B.; Rosner, W.; Pi-Sunyer, X. (1994). "The relationship between serum levels of insulin and sex hormone-binding globulin in men: The effect of weight loss". The Journal of clinical endocrinology and metabolism 79 (4): 1173–1176. PMID 7962291. edit
- ^ Pasquali, R.; Casimirri, F.; De Iasio, R.; Mesini, P.; Boschi, S.; Chierici, R.; Flamia, R.; Biscotti, M. et al. (1995). "Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men". The Journal of clinical endocrinology and metabolism 80 (2): 654–658. PMID 7852532. edit
- ^ Ducluzeau, P. H.; Cousin, P.; Malvoisin, E.; Bornet, H.; Vidal, H.; Laville, M.; Pugeat, M. (2003). "Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome". The Journal of clinical endocrinology and metabolism 88 (8): 3626–3631. PMID 12915646. edit
- ^ Starka, L.; Duskova, M.; Cermakova, I.; Vrbiková, J.; Hill, M. (2005). "Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome?". Endocrine regulations 39 (4): 127–131. PMID 16552990. edit
- ^ Tymchuk, C. N.; Tessler, S. B.; Barnard, R. J. (2000). "Changes in Sex Hormone-Binding Globulin, Insulin, andSerum Lipids in Postmenopausal Women on aLow-Fat, High-Fiber Diet Combined with Exercise". Nutrition and Cancer 38 (2): 158–162. doi:10.1207/S15327914NC382_3. PMID 11525592. edit
- ^ Sallinen, J.; Pakarinen, A.; Fogelholm, M.; Alen, M.; Volek, J.; Kraemer, W.; Häkkinen, K. (2007). "Dietary Intake, Serum Hormones, Muscle Mass and Strength During Strength Training in 49 - 73-Year-Old Men". International Journal of Sports Medicine 28 (12): 1070–1076. doi:10.1055/s-2007-965003. PMID 17497592. edit
- ^ Nielsen, T. L.; Hagen, C.; Wraae, K.; Brixen, K.; Petersen, P. H.; Haug, E.; Larsen, R.; Andersen, M. (2007). "Visceral and Subcutaneous Adipose Tissue Assessed by Magnetic Resonance Imaging in Relation to Circulating Androgens, Sex Hormone-Binding Globulin, and Luteinizing Hormone in Young Men". Journal of Clinical Endocrinology & Metabolism 92 (7): 2696–2705. doi:10.1210/jc.2006-1847. PMID 17426100. edit
- ^ Bonnet, F.; Cephise, F. L. V.; Gautier, A.; Dubois, S. V.; Massart, C.; Camara, A.; Larifla, L.; Balkau, B. et al. (2012). "Role of sex steroids, intra-hepatic fat and liver enzymes in the association between SHBG and metabolic features". Clinical Endocrinology: n/a. doi:10.1111/cen.12089. PMID 23121021. edit
- ^ Van Rossum, E. F. C.; Lamberts, S. W. J. (2006). "Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach". Best Practice & Research Clinical Endocrinology & Metabolism 20 (4): 611–626. doi:10.1016/j.beem.2006.09.005. PMID 17161335. edit
- ^ Devarakonda, K.; Martha, S.; Pantam, N.; Thungathurthi, S.; Rao, V. (2008). "Study of insulin resistance in relation to serum IGF-I levels in subjects with different degrees of glucose tolerance". International Journal of Diabetes in Developing Countries 28 (2): 54–59. doi:10.4103/0973-3930.43100. PMC 2772007. PMID 19902049. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2772007/. edit
- ^ a b Rosenfeld, Ron G. (Nov 9, 2010). [ISBN 1617371386 The IGF System: Molecular Biology, Physiology, and Clinical Applications (Contemporary Endocrinology)]. umana Press. ISBN 1617371386.
- ^ Staff (Jun 22, 2012). "Why bald men never went extinct: 4 theories". The Week. http://theweek.com/article/index/229694/why-bald-men-never-went-extinct-4-theories. Retrieved Dec 16, 2012.
- ^ Muscarella, Frank; Cunningham, Mark (1992). "The evolutionary significance and social perception of male pattern baldness and facial hair". Ethology and Sociobiology (Elsevier Inc.) 17 (2): 99–117. http://www.sciencedirect.com/science/article/pii/0162309595001301. Retrieved Dec 16, 2012.
- ^ Dunn, Robb (2012). "Why haven't bald men gone extinct?". New Scientist (NewScientist.com) 2869. http://www.newscientist.com/article/mg21428692.100-why-havent-bald-men-gone-extinct.html?full=true. Retrieved Dec 16, 2012.
- ^ Kabai, P. (2010). "Might early baldness protect from prostate cancer by increasing skin exposure to ultraviolet radiation?". Cancer Epidemiology 34 (4): 507. doi:10.1016/j.canep.2010.04.014. PMID 20451486. edit
- ^ Kabai, P. (2008). "Androgenic alopecia may have evolved to protect men from prostate cancer by increasing skin exposure to ultraviolet radiation". Medical Hypotheses 70 (5): 1038–1040. doi:10.1016/j.mehy.2007.07.044. PMID 17910907. edit
- ^ Cash, T. F. (1999). "The psychosocial consequences of androgenetic alopecia: A review of the research literature". The British journal of dermatology 141 (3): 398–405. PMID 10583042. edit
- ^ Cash, T. F. (1992). "The psychological effects of androgenetic alopecia in men". Journal of the American Academy of Dermatology 26 (6): 926–931. PMID 1607410. edit
- ^ Diagnosing Men's Hair Loss: Norwood Scale Chart. Webmd.com (2010-03-01). Retrieved on 2010-11-28.
- ^ Rudnicka, L.; Olszewska, M.; Rakowska, A.; Kowalska-Oledzka, E.; Slowinska, M. (2008). "Trichoscopy: A new method for diagnosing hair loss". Journal of drugs in dermatology : JDD 7 (7): 651–654. PMID 18664157. edit
- ^ Mounsey, A. L.; Reed, S. W. (2009). "Diagnosing and treating hair loss". American family physician 80 (4): 356–362. PMID 19678603. edit
- ^ Yoo, H. G.; Kim, J. S.; Lee, S. R.; Pyo, H. K.; Moon, H. I.; Lee, J. H.; Kwon, O. S.; Chung, J. H. et al. (2006). "Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia". Biological & pharmaceutical bulletin 29 (6): 1246–1250. PMID 16755026. edit
- ^ Rashid, R. M.; Thomas, V. (2010). "Androgenic pattern presentation of scarring and inflammatory alopecia". Journal of the European Academy of Dermatology and Venereology 24 (8): 979–980. doi:10.1111/j.1468-3083.2009.03557.x. PMID 20059630. edit
- ^ "Propecia (Finasteride) Drug Information: User Reviews, Side Effects, Drug Interactions and Dosage". RxList. Mar 13, 2010. http://www.rxlist.com/propecia-drug.htm. Retrieved Nov 28, 2010.
- ^ Hajheydari, Z.; Akbari, J.; Saeedi, M.; Shokoohi, L. (2009). "Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia". Indian journal of dermatology, venereology and leprology 75 (1): 47–51. PMID 19172031. edit
- ^ Caroli, S.; Pathomvanich, D.; Amonpattana, K.; Kumar, A. (2011). "Current status of hair restoration surgery". International surgery 96 (4): 345–351. PMID 22808618. edit
- ^ Rose, P. (2011). "The Latest Innovations in Hair Transplantation". Facial Plastic Surgery 27 (4): 366–377. doi:10.1055/s-0031-1283055. PMID 21792780. edit
- ^ Elisabeth Leamy (May 31, 2012). "Considering a hair tattoo? Pro's and cons to consider before you commit". ABC News. http://abcnews.go.com/blogs/health/2012/05/31/considering-a-hair-tattoo-pros-and-cons-to-consider-before-you-commit/. Retrieved Dec 16, 2012.
- ^ Bella Battle (Feb 11, 2012). "Wish you were hair". The Sun. http://www.thesun.co.uk/sol/homepage/features/4121987/News-Bald-men-can-try-out-new-hair-scalp-tattoo.html. Retrieved Dec 16, 2012.
- ^ Ghanaat, M. (2010). "Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism". Southern Medical Journal 103 (9): 917–921. doi:10.1097/SMJ.0b013e3181ebcf71. PMID 20689478. edit
- ^ Foitzik, K.; Hoting, E.; Förster, T.; Pertile, P.; Paus, R. (2007). "L-Carnitine–L-tartrate promotes human hair growth in vitro". Experimental Dermatology 16 (11): 936–945. doi:10.1111/j.1600-0625.2007.00611.x. PMID 17927577. edit
- ^ Edwards, Jim (12 January 2011). "Pharma's 4 Best Shots at a Cure for Baldness". CBSNews.com. CBS News. http://www.cbsnews.com/8301-505123_162-42847047/pharmas-4-best-shots-at-a-cure-for-baldness/. Retrieved 1 August 2012.
- ^ Kang, II, J.; Kim, S.-C (2012). "Hair-loss preventing effect of Grateloupia elliptica". Biomolecules & Therapeutics 20 (1): 118–124. http://stemcellbaldnesscures.com/wp-content/uploads/2012/07/Grateloupia-elliptica-hair-loss.pdf. Retrieved December 9, 2012.
- ^ Nguyen, H; Kim, S. M (2012). "Antioxidative, anticholinesterase and antityrosinase activities of the red alga Grateloupia lancifolia extracts". African Journal of Biotechnology 11 (39): 9547-9467. http://academicjournals.org/ajb/PDF/pdf2012/15May/Nguyen%20and%20Kim.pdf. Retrieved December 9, 2012.
- ^ Castro, R. F.; Azzalis, L. A.; Feder, D.; Perazzo, F. F.; Pereira, E. C.; Junqueira, V. B. C.; Rocha, K. C.; Machado, C. D. A. et al. (2012). "Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model". Clinical and Experimental Dermatology 37 (8): 909–912. doi:10.1111/j.1365-2230.2012.04441.x. PMID 22924775. edit
- ^ Sara Malm. "Baldness cure which reverses genetics could start clinical trials in two years". Daily Mail. http://www.dailymail.co.uk/news/article-2190544/Baldness-cure-reverses-genetics-market-years.html. Retrieved 2012-11-16.
- ^ Stephen Adams (Aug 19, 2012). "Baldness cure could be on shelves in two years". The Telegraph. http://www.telegraph.co.uk/health/healthnews/9485807/Baldness-cure-could-be-on-shelves-in-two-years.html. Retrieved 2012-11-16.
- ^ Anne Eisenberg (2012-07-29). "Baldness Battle, Fought in the Follicle". The New York Times. http://www.nytimes.com/2012/07/29/business/baldness-battle-fought-in-the-follicle.html.
External links
- NLM- Genetics Home Reference
- Scow, Dean Thomas; Nolte, Robert S.; Shaugnessy, Allen F. (April 1999). "Medical treatments for balding in men". American family physician 59 (8): 2189–2194, 2196. PMID 10221304. http://www.aafp.org/afp/990415ap/2189.html.
- Kabai, P (2008). "Androgenic alopecia may have come about to protect men from prostate cancer by increasing skin exposure to ultraviolet radiation". Medical Hypotheses 70 (5): 1038–1040. doi:10.1016/j.mehy.2007.07.044. PMID 17910907.
- How Hair Replacement Works Covers oral medications, hair transplant surgery, and topical treatments.
- Male Pattern Baldness Genetics
- Article examining the impact of baldness on career success from USA Today
Disorders of skin appendages (L60–L75, 703–706)
|
|
Nail |
- thickness: Onychogryphosis
- Onychauxis
- color: Beau's lines
- Yellow nail syndrome
- Leukonychia
- Azure Lunula
- shape: Koilonychia
- Nail clubbing
- behavior: Onychotillomania
- Onychophagia
- other: Ingrown nail
- Anonychia
- ungrouped: Paronychia
- Acute paronychia
- Chronic paronychia
- Chevron nail
- Congenital onychodysplasia of the index fingers
- Green nails
- Half and half nails
- Hangnail
- Hapalonychia
- Hook nail
- Lichen planus of the nails
- Longitudinal erythronychia
- Malalignment of the nail plate
- Median nail dystrophy
- Mees' lines
- Melanonychia
- Muehrcke's lines
- Nail–patella syndrome
- Onychoatrophy
- Onychocryptosis
- Onycholysis
- Onychomadesis
- Onychomatricoma
- Onychomycosis
- Onychophosis
- Onychoptosis defluvium
- Onychorrhexis
- Onychoschizia
- Platonychia
- Pincer nails
- Plummer's nail
- Psoriatic nails
- Pterygium inversum unguis
- Pterygium unguis
- Purpura of the nail bed
- Racquet nail
- Red lunulae
- Shell nail syndrome
- Splinter hemorrhage
- Spotted lunulae
- Staining of the nail plate
- Stippled nails
- Subungual hematoma
- Terry's nails
- Twenty-nail dystrophy
|
|
Hair |
|
|
Sweat glands |
Eccrine |
- Miliaria
- Colloid milium
- Miliaria crystalline
- Miliaria profunda
- Miliaria pustulosa
- Miliaria rubra
- Occlusion miliaria
- Postmiliarial hypohidrosis
- Granulosis rubra nasi
- Ross’ syndrome
- Anhidrosis
- Hyperhidrosis
- Generalized
- Gustatory
- Palmoplantar
|
|
Apocrine |
- Body odor
- Chromhidrosis
- Fox–Fordyce disease
|
|
Sebaceous |
|
|
|
|
|
noco/cong/tumr, sysi/epon
|
|
|
|
|